# Dupixent

NDC: 0024-5919
Generic name: Dupilumab
Labeler / Manufacturer: Sanofi-Aventis U.S. LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20210614

FDA application: BLA761055

## Active ingredients

- DUPILUMAB: 200 mg/1.14mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0024-5919"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0024-5919
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780